Skip to main content

MEDIFAST INC

corporate_fare Company Profile

MEDIFAST INC

MED·NYSE·Consumer Cyclical·CIK 0000910329

Medifast, Inc. is a health and wellness company with over 40 years of experience, known for its science-backed, coach-guided lifestyle system. As of 2026, the company is focusing on execution, using its experience in structured weight loss and recent scientific research and product enhancements to serve the broader metabolic health market. Medifast addresses the root cause of metabolic dysfunction. This strategy targets a larger and more sustainable market, aiming for long-term growth over the next decade by aligning science, products, and coaching with increasing demand for solutions as awareness of metabolic dysfunction grows. This growth is supported by improving coach productivity and expanding the coach network. The company operates a well-capitalized business with a lifestyle solution and a business model that has impacted over 3 million lives. For the quarter ended December 31, 2025, Medifast had a network of approximately 16,100 active earning independent coaches. Medifast offers evidence-based wellness solutions, and its coach-first model creates opportunities for coaches' individual businesses. This model is designed to create a "flywheel effect" where new clients join, increasing coach productivity, which attracts new active earning coaches, leading to more new clients and further productivity. The company provides a comprehensive approach to achieving optimal metabolic health and well-being, empowering individuals to make lasting changes. Clients are guided by coaches, approximately 90% of whom were clients first, through their wellness journey. Scientifically developed products and a habit creation framework, reinforced by coaches and community support, provide health benefits and serve as a foundation for a comprehensive metabolic health system. Medifast innovates based on its scientific and clinical heritage to achieve its mission of Lifelong Transformation, Making a Healthy Lifestyle Second Nature®. Coaches provide support, community, nutrition, and healthy habits.

MEDIFAST INC (NYSE:MED) is a publicly traded company in the Consumer Cyclical sector. Wiseek monitors MED SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Medifast Reports Worsening Q1 2026 Results with 34% Revenue Drop and Expanded Net Loss
  • Medifast Forecasts Q2 Loss of $0.50-$1.00/Share Amid Continued Struggles
  • Medifast Q1 Revenue Plunges 34% as Coach Count Drops 45%, Projects Continued Losses
  • Medifast Reports Steep Q1 Revenue Decline, Increased Losses, and Negative 2026 Outlook Amid Industry Headwinds
  • Medifast Amends Share Incentive Plan Proposal with Post-Exercise Holding Requirement Following ISS Feedback

monitoring Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$385.79M
Net Income
-$18.67M
Diluted EPS
-$1.70
Op. Cash Flow
$6.86M
Free Cash Flow
$1.25M
Gross Profit
$275.19M
Operating Income
-$14.21M
Cash & Equivalents
$89.3M
Debt / Equity
0.00×
Net Margin
-4.8%
Shares Outstanding
10.99M sh
Source: 10-K · filed 2026-02-17 · accession 0001628280-26-008656

supervised_user_circle Insider Transactions

$246.68K bought
Net $246.68K buying · 4 transactions by 2 insiders · last 12 months
  • 2026-05-11 SCHLACKMAN SCOTT Director
    Open-market purchase 2.5K sh $31.32K @ $12.53
  • 2026-05-08 SCHLACKMAN SCOTT Director
    Open-market purchase 2.5K sh $31.63K @ $12.65
  • 2026-03-20 Chard Daniel R Chairman & CEO Officer · Director
    Open-market purchase 17.68K sh $178.72K @ $10.11
  • 2025-06-13 Chard Daniel R Chairman & CEO Officer · Director
    Open-market purchase 381 sh $5K @ $13.13
  • 2026-03-25 Chard Daniel R Chairman & CEO Officer · Director
    Grant/Award 41.8K sh 2 fills
  • 2026-03-25 Chard Daniel R Chairman & CEO Officer · Director
    Tax/exercise cost 20.09K sh $192.71K @ $9.59
  • 2026-03-25 Maloney James P. Chief Financial Officer Officer
    Tax/exercise cost 3.22K sh $30.92K @ $9.59
  • 2026-03-25 Maloney James P. Chief Financial Officer Officer
    Grant/Award 35.36K sh 2 fills
  • 2026-03-25 MacKenzie Jonathan Barrett VP, Finance & CAO Officer
    Tax/exercise cost 862 sh $8.27K @ $9.59
  • 2026-03-25 MacKenzie Jonathan Barrett VP, Finance & CAO Officer
    Grant/Award 10.83K sh
  • 2026-03-17 Chard Daniel R Chairman & CEO Officer · Director
    Tax/exercise cost 2.64K sh $26.51K @ $10.05
  • 2026-03-17 Maloney James P. Chief Financial Officer Officer
    Tax/exercise cost 482 sh $4.84K @ $10.05
  • 2026-03-17 MacKenzie Jonathan Barrett VP, Finance & CAO Officer
    Tax/exercise cost 70 sh $703.5 @ $10.05
  • 2026-03-13 Chard Daniel R Chairman & CEO Officer · Director
    Tax/exercise cost 7.08K sh $68.06K @ $9.62
  • 2026-03-13 Maloney James P. Chief Financial Officer Officer
    Tax/exercise cost 918 sh $8.83K @ $9.62
  • 2026-03-13 MacKenzie Jonathan Barrett VP, Finance & CAO Officer
    Tax/exercise cost 198 sh $1.9K @ $9.62
  • 2025-06-25 BROWN JEFFREY J Director
    Grant/Award 20.62K sh $126.53K 2 fills, avg $6.14
  • 2025-06-25 SCHLACKMAN SCOTT Director
    Grant/Award 11.17K sh
  • 2025-06-25 Hoer Michael A. Director
    Grant/Award 11.17K sh
  • 2025-06-25 Xian Ming Director
    Grant/Award 17.18K sh $80.52K 2 fills, avg $4.69 derivative
  • 2025-06-25 Thomas Andrea B Director
    Grant/Award 11.17K sh
  • 2025-06-25 Geary Elizabeth A. Director
    Grant/Award 11.17K sh
From SEC Form 4 + 5 (insider beneficial-ownership filings) · last 12 months · view all on SEC EDGAR ↑
$12.63
52-week range $9.22 – $15.46
Market cap
$140.43M
Volume
208.3K (1.0× avg)
3-mo avg 206.6K
Price snapshot as of 2026-05-22 01:52 UTC (Market snapshot (OVERNIGHT))

show_chartPrice Chart

Loading chart...

feed MED - Latest Insights

MED
May 04, 2026, 4:51 PM EDT
Filing Type: 10-Q
Importance Score:
8
MED
May 04, 2026, 4:32 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
MED
May 04, 2026, 4:17 PM EDT
Source: Reuters
Importance Score:
8
MED
May 04, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
8
MED
Apr 30, 2026, 9:24 AM EDT
Filing Type: DEFA14A
Importance Score:
8
MED
Apr 06, 2026, 4:06 PM EDT
Filing Type: DEF 14A
Importance Score:
8
MED
Mar 27, 2026, 5:51 PM EDT
Filing Type: 4
Importance Score:
7
MED
Mar 20, 2026, 12:55 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
9
MED
Mar 20, 2026, 8:35 AM EDT
Filing Type: 8-K
Importance Score:
8
MED
Feb 17, 2026, 4:54 PM EST
Filing Type: 10-K
Importance Score:
9
MED
Feb 17, 2026, 4:44 PM EST
Filing Type: 8-K
Importance Score:
8
MED
Jan 05, 2026, 9:02 AM EST
Filing Type: 8-K
Importance Score:
8